-+ 0.00%
-+ 0.00%
-+ 0.00%

Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255

Benzinga·08/07/2026 14:13:49
Listen to the news
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $260 to $255.